To further validate our platform, we made use of the fact that TP53-wild-type tumors can be responsive to MDM2 inhibitors, as the tumor suppressor function of p53 is frequently impaired due to enhanced activity of its upstream negative regulator MDM2. This evidence concerns the gene MDM2 and neoplasm.